openPR Logo
Press release

RNAi Therapeutics Market Forecast Covering Growth Development Strategies till 2027 - Arbutus Biopharma Corporation, Silence Therapeutics, Rexahn Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd, Quark

11-15-2019 08:26 AM CET | Science & Education

Press release from: The Insight Partners

The Insight Partners

The Insight Partners

The global RNAi Therapeutics market is segmented on the basis of molecule type, application, route of administration, and end user. Based on the molecule type the market is segmented as small interfering RNAs (siRNA), and microRNA (miRNA). On the basis of application the market is classified as genetic disorders, oncology, neurodegenerative disorders, cardiovascular, respiratory disorders, infectious diseases, renal diseases, and others. Based on the route of administration the market is categorized as intradermal injections, pulmonary delivery, intravenous injections, intraperitoneal injections, and others. And on the basis of end user the market is divided into diagnostic laboratories, research and academic laboratories, and hospitals

RNA interference is a biological method in which molecules of RNA inhibit gene expression by neutralizing the targeted mRNA molecules. This method plays vital role in defending cells against virus. This technique is an innovative method which into the clinical trial phase, and various companies are seeking for the FDA and EU commission approval for their products and technologies. The RNAi therapeutic are formulated to treat diseases such as cancer, haemophilia, age related diseases, and others.

Get Sample PDF Copy at

The RNAi therapeutics market is forecasted to grow due to the key factors such as rising chronic diseases such as cancer, genetic disorders, and cardiovascular diseases among others. The growth of the market is also expected to grow due to rising technological development and growing FDA approvals for RNAi therapeutics. The growth of the market is expected to have growth opportunities in the emerging nations were healthcare facilities and developments are rising significantly.

The "Global RNAi Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a special focus on the global market trend analysis. The report aims to provide an overview of RNAi therapeutics market with detailed market segmentation by molecule type, application, route of administration, end user and geography. The global RNAi therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading RNAi therapeutics market players and offers key trends and opportunities in the market.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global RNAi therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The RNAi therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

Top Companies Listed are -
1. Alnylam Pharmaceuticals, Inc.
2. Sanofi
4. GlaxoSmithKline plc
5. Benitec Biopharma
6. Arbutus Biopharma Corporation
7. Silence Therapeutics
8. Rexahn Pharmaceuticals, Inc
9. F. Hoffmann-La Roche Ltd
10. Quark

The report also includes the profiles of key RNAi therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

Buy Complete Report at

Contact us –
Phone : +1-646-491-9876
Email Id :

About Us - The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release RNAi Therapeutics Market Forecast Covering Growth Development Strategies till 2027 - Arbutus Biopharma Corporation, Silence Therapeutics, Rexahn Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd, Quark here

News-ID: 1867854 • Views: 307

More Releases from The Insight Partners

Nutraceuticals Market 2019 Global Industry Size, Share, Revenue, Business Growth …
The Insight Partners’ report on the Nutraceuticals Market aims at developing a better understanding of the Nutraceuticals industry through qualitative and quantitative analysis of the key market parameters. The Nutraceuticals market is classified on the basis of type and application, and the market is evaluated in terms of growth, value, and volume across five major geographical regions. The report also includes the profiles of key nutraceuticals companies along with their SWOT
Laboratory Informatics Market 2019 Global Overview by Thermo Fisher Scientific I …
A Detailed Laboratory Informatics Market SWOT analysis provides strategic information on the strengths and weaknesses of key players in the market, categories and country growth prospects, challenges and intimidation from current competition and future growth prospects, and global and regional market positions. Request a Sample PDF Copy at The "Global Laboratory Informatics Market Analysis to 2027" is a specialized and in-depth study of the laboratory informatics industry with a focus on
Automotive Leasing Market 2019: Emerging Top Key Player Like ALD Automotive, Arv …
The Automotive Leasing Market report aims to provide a 360-degree view of the market in terms of cutting-edge technology, key developments, drivers, restraints and future trends with impact analysis of these trends on the market for short-term, mid-term and long-term during the forecast period. Further, the report also covers key players profiling with detailed SWOT analysis, financial facts and key developments of products/service from the past three years. Get Sample Copy
Global Cooling Fabrics Market 2019 Competition Landscape 2027 | Adidas AG, Ahlst …
The cooling fabrics market is anticipated to grow in the forecast period owing to driving factors such as innovations in the field of textiles with growing concerns towards health and safety of workers. Moreover, rising popularity of cooling fabrics in sports and leisure activities further fuel the cooling fabrics market growth. However, high prices of the product and low penetration in the end-user market segment hinders market growth. Nonetheless, the

All 5 Releases

More Releases for RNA

RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
RNA Sequencing: Technologies and Analyses of Global Market Trends
"The Latest Research Report RNA Sequencing: Technologies and Global Markets provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. -" The global RNA-Sequencing market reached nearly $1.1 billion in 2015, and should reach $1.2 billion in 2016 and $2.1 billion in 2020, registering a compound annual growth rate (CAGR) of 14.9%. The tools and reagents segment should reach over $1.0 billion in 2020 from $566.8
Topics Presented this February 2018 at RNA Therapeutics
SMi’s RNA Therapeutics will be bringing a global presence from MHRA, The RNA Institute, MiNA Therapeutics, AstraZeneca R&D, GSK, Sanofi, CureVac and more. With an agenda full of exciting and new approaches, examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches and patenting RNA Therapeutics. Spotlight: Want to learn about exploiting exosomes for therapeutic use in patients with cystic fibrosis? Have questions answered during
RNA Analysis Market worth 3.62 billion USD by 2021
RNA Analysis Market size was around USD 1.89 billion in 2016. It is expected to grow at a CAGR of 13.9% to reach USD 3.62 billion by 2021. The market is mainly driven by the increasing technological advancements, increasing investment in research and development by biotechnology and pharmaceutical companies, rising government and private funding, and growing preference for personalized medicines. However, lack of skilled professionals in the transcriptomics field and lack
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led